Available Until 2/14/2023

Oncology Pharmacy Specialty Review Course, Workbook Chapters (No Recert Credit (Cert # L229087))

ACPE Numbers: Various – see listing below
Pre-Sale Date: 03/17/2022
Content Release Date: 03/30/2022
Expiration Date: 02/14/2023
Activity Type: Application-based
CE Credits: 25.75 hours (ACPE only)
Activity Fee: $425 (ASHP member); $625 (non-member)

These activities were recorded during a live educational event on March 3-5, 2022, at the ACCP/ASHP’s 2022 Live Review & Recertification Courses, Henderson, Nevada. Learners who claimed credit for the live activities should not claim credit for these home study activities.

Activity Overview

This online course provides a robust preparatory curriculum for the pharmacy professional preparing for the Board of Pharmacy Specialties (BPS) Oncology Specialty Certification Examination. Designed based on the domains, tasks, and knowledge statements developed by the BPS for the certification examination, this course will help you prepare for the exam by identifying areas needed for an in‐depth review of oncology issues by:

  • Reviewing pertinent clinical topics and practice skills
  • Listing valuable references for further study

This course is NOT intended for those obtaining recertification credit. To earn recertification credit, please see courses here: http://elearning.ashp.org/catalog/onc-recert

These activities are part of the ASHP and ACCP professional development program.

Accreditation

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These activities are intended for pharmacists who are seeking to update their knowledge and skills commensurate with a board certification examination in the areas listed below.

Review Course

This course consists of 20 activities (see table below) and provides up to 25.75 hours of continuing pharmacy education credit. The Review Course includes case-based presentations for application to real-life scenarios and links to the reference sources, domains, tasks, and knowledge statements.          

Learning Activity

ACPE Number

Contact Hours

Expiration Date

Breast Cancer

0204-9999-22-912-H01-P

2.5

03/04/2025

Gynecologic Malignancies

0204-9999-22-913-H01-P

1.0

Prostate Cancer

0204-9999-22-914-H01-P

1.0

Pediatric Malignancies and Supportive Care

0204-9999-22-915-H01-P

1.25

Upper Gastrointestinal and Hepatocellular Carcinomas

0204-9999-22-916-H01-P

0.75

Bladder, Renal Cell, and Testicular Cancers

0204-9999-22-929-H01-P

1.0

Melanoma and Non-Melanoma Skin Cancers

0204-9999-22-917-H01-P

1.0

Research Design, Statistics, and Evaluating Oncology Literature

0204-9999-22-918-H04-P

2.0

Adult Acute Leukemias and Myelodysplastic Syndromes

0204-9999-22-919-H01-P

1.5

Lymphomas

0204-9999-22-920-H01-P

1.25

Chronic Leukemias

0204-9999-22-921-H01-P

1.5

Hematopoietic Stem Cell Transplantation

0204-9999-22-922-H01-P

1.25

Lung Cancer

0204-9999-22-923-H01-P

1.5

Lower Gastrointestinal and Pancreatic Cancers

0204-9999-22-924-H01-P

1.25

Head, Neck, Adult Central Nervous System  (CNS), and Thyroid Malignancies

0204-9999-22-930-H01-P

1.0

Cancer-related Infectious Diseases

0204-9999-22-931-H01-P

1.0

Oncology Practice Management

0204-9999-22-925-H04-P

2.0

Multiple Myeloma

0204-9999-22-926-H01-P

1.5

Adult Sarcomas

0204-9999-22-927-H01-P

0.75

Pharmacogenomics in Oncology

0204-9999-22-928-H01-P

0.75

Learning Objectives

At the end of the presentations, the pharmacist should be able to:

Breast Cancer
ACPE #: 0204-9999-22-912-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with breast cancer.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with breast cancer and her or his caregiver.
  • Determine appropriate pharmacotherapy for a patient with breast cancer based on genomic test results.
  • Identify appropriate diagnostic and prognostic tests related to breast cancer.
  • Select relevant information and guidance for the public regarding breast cancer-related issues (e.g., cancer risk factors, prevention, screening).

Gynecologic Malignancies
ACPE #: 0204-9999-22-913-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes of clinical trials and current treatment guidelines for a patient with a gynecologic malignancy.
  • Discuss short and long-term goals, including post-therapy and survivorship, with a patient with a gynecologic malignancy and her caregiver.
  • Select relevant information and provide guidance for the public regarding gynecologic malignancy‐related issues (e.g., risk factors, prevention, and screening).

Prostate Cancer
ACPE #: 0204-9999-22-914-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with prostate cancer.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with prostate cancer and his caregiver.
  • Select relevant information and guidance for the public regarding prostate cancer-related issues (e.g., risk factors, prevention, screening). 

Pediatric Malignancies and Supportive Care
ACPE #: 0204-9999-22-915-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for pediatric patients with cancer.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing for a pediatric patient with cancer.
  • Discuss with a pediatric patient who has cancer and his or her caregiver the short- and long-term treatment goals, including post-therapy and survivorship.
  • Assess the regulatory, ethical, and patient rights issues related to conducting research, including informed consent and confidentiality.

Upper Gastrointestinal and Hepatocellular Carcinomas
ACPE #: 0204-9999-22-916-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with esophageal, gastric, or hepatic malignancies.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer agents used for gastrointestinal malignancies.
  • Develop an appropriate plan for preventing, monitoring, and treating radiation recall and other complications of radiation therapy.

Bladder, Renal Cell, and Testicular Cancers
ACPE #: 0204-9999-22-929-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal, or testicular carcinomas.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with bladder, renal, or testicular carcinomas and his or her caregiver.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment with tyrosine kinase inhibitors and mTOR inhibitors. 

Melanoma and Non-Melanoma Skin Cancers
ACPE #: 0204-9999-22-917-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with melanoma or non-melanoma skin cancer.
  • Discuss short- and long-term goals, including post-therapy and survivorship, with a patient with melanoma or non-melanoma skin cancer and his or her caregiver.
  • Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of melanoma and non-melanoma skin cancers, including thyroid level monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAF inhibitors. 

Research Design, Statistics, and Evaluating Oncology Literature
ACPE #: 0204-9999-22-918-H04-P

  • Evaluate the oncology literature, including study design, identification of sources of bias, methodology, statistical analysis, and applicability of results to clinical practice for the oncology patient population.
  • Interpret the validity and results of various types of oncology studies (e.g., meta-analyses, noninferiority trials).
  • Interpret findings from the use of study endpoints (e.g., objective response, time to progression, adverse events, quality of life, overall survival) in oncology research.
  • Interpret sensitivity, specificity, positive and negative predictive values, measures of effect, correlation, and regression for an oncology study. 

Adult Acute Leukemias and Myelodysplastic Syndromes
ACPE #: 0204-9999-22-919-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adults with acute leukemia or myelodysplastic syndrome.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing for an adult with acute leukemia or myelodysplastic syndrome.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions from pharmacotherapy for acute leukemia and myelodysplastic syndrome in an adult, including tumor lysis syndrome, neurotoxicity, differentiation syndrome, and cardiac toxicity from arsenic trioxide, and other agents as appropriate.
  • Determine appropriate pharmacotherapy for acute leukemia or myelodysplastic syndrome in an adult based on genomic test results. 

Lymphomas
ACPE #: 0204-9999-22-920-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities and outcomes, based on the most current guidelines for patients with lymphoma.
  • Assess the prognostic impact of relevant cancer‐related molecular biology testing.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation. 

Chronic Leukemias
ACPE #: 0204-9999-22-921-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration relevant molecular biology testing, genomic information, efficacy and safety outcomes from clinical trials, and current treatment guidelines for patients with chronic leukemia.
  • Develop an appropriate plan for preventing, monitoring, and treating infusion‐related reactions from monoclonal antibodies used in the treatment of hematologic malignancies.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for the treatment of cancers, including toxicities from tyrosine kinase inhibitors used to treat hematologic cancers.

Hematopoietic Stem Cell Transplantation
ACPE #: 0204-9999-22-922-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients undergoing hematopoietic stem cell transplantation (HSCT).
  • Apply appropriate strategies to prevent and treat toxicity from chemotherapy agents employed in HSCT conditioning regimens.
  • Create a plan for prevention and management of acute and chronic graft‐versus‐host disease (GVHD) using appropriate systemic and ancillary therapies. 
  • Discuss short‐ and long‐term treatment goals, including post-therapy and survivorship, with the patient undergoing HSCT and his or her caregiver.

Lung Cancer
ACPE #: 0204-9999-22-923-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lung cancer.
  • Select relevant information and guidance for the public regarding lung cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lung cancer.
  • Develop a prevention and management strategy for chemotherapy-induced nausea and vomiting for patients with any type of cancer. 

Lower Gastrointestinal and Pancreatic Cancers
ACPE #: 0204-9999-22-924-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lower gastrointestinal (GI) or pancreatic cancers.
  • Discuss short‐ and long‐term treatment goals, including post‐therapy and survivorship, with a patient with lower GI or pancreatic cancers and his or her caregiver.
  • Select relevant information and guidance for the public regarding lower GI and pancreatic cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lower GI or pancreatic cancers, including chemotherapy-induced diarrhea, hand‐foot syndrome, hand-foot skin reaction, neurotoxicity from oxaliplatin, and dermatologic toxicities from epidermal growth factor receptor inhibitors. 

Head, Neck, Adult Central Nervous System  (CNS), and Thyroid Malignancies
ACPE #: 0204-9999-22-930-H01-P

  • Design an appropriate patient‐specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, adult central nervous system (CNS), or thyroid cancers.
  • Select relevant information and guidance for the public regarding head and neck cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cancer cachexia, mucositis, and xerostomia. 

Cancer-related Infectious Diseases
ACPE #: 0204-9999-22-931-H01-P

  • Design an appropriate patient-specific management and monitoring plan to address potential infection-related problems that may arise during and following cancer treatment based on current guidelines for treating cancer-related infectious diseases.
  • Discuss short- and long-term treatment goals, including post-therapy, with a patient with cancer-related infectious disease and his or her caregiver.

Oncology Practice Management
ACPE #: 0204-9999-22-925-H04-P

  • Evaluate oncology pharmacy services for compliance with established regulations, professional practice standards, and procedures for safe handling, administration, and disposal of hazardous drugs.
  • Select quality-improvement activities that enhance the safety and effectiveness of the medication-use process in oncology patient care.
  • Explain national accreditation and federal regulatory requirements for the care of cancer patients receiving chemotherapy or other hazardous drugs.
  • Explain medication reimbursement and patient assistance programs to optimize drug availability for oncology patients.
  • Evaluate policies and procedures related to conducting research involving investigational drugs, including drug management in patients with cancer.

Multiple Myeloma
ACPE #: 0204-9999-22-926-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with multiple myeloma.
  • Evaluate oncology pharmacy services for compliance with established REMS regulations and standards.
  • Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of cancers, including bone metastases, thromboembolism, hypercalcemia of malignancy, and spinal cord compression.

Adult Sarcomas
ACPE #: 0204-9999-22-927-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma.
  • Adjust treatment and monitoring plans as needed based on the tumor genetics and pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate).
  • Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of adult patients with cancer, including neurotoxicity from ifosfamide and hemorrhagic cystitis 

Pharmacogenomics in Oncology
ACPE #: 0204-9999-22-928-H01-P

  • Identify appropriate considerations for genetic interpretation in both the germline and somatic settings utilizing a variety of next generation sequencing techniques.
  • Apply the results from somatic and germline genetic testing into therapy recommendations based on prognostic, predictive and patient characteristics.
  • Recognize the place in therapeutic decision making for companion diagnostic testing.

Faculty

Jessica Auten, Pharm.D., BCOP
Clinical Pharmacy Specialist, Acute Care Malignant Hematology
UNC Medical Center
Chapel Hill, North Carolina

John Bossaer, Pharm.D., BCPS, BCOP
Professor
Bill Gatton College of Pharmacy at ETSU
Johnson City, Tennessee

Courtney C. Cavalieri, Pharm.D., BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Brette Conliffe, Pharm.D., BCOP
Clinical Oncology Pharmacist
University of Louisville Health/Brown Cancer Center
Louisville, Kentucky

Karen M. Fancher, Pharm.D., BCOP*
Associate Professor of Pharmacy Practice/ Clinical Pharmacy Specialist - Oncology
Duquesne University School of Pharmacy/UPMC Passavant Hospital
Pittsburgh, Pennsylvania

Christopher Fausel, Pharm.D., M.H.A., BCOP
Clinical Specialist – Precision Medicine
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana

Kelly Fritz, Pharm.D., BCOP
Oncology Clinical Coordinator
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Lauren Ice, Pharm.D., BCOP, BCPS
Clinical Pharmacy Specialist
Spectrum Health
Grand Rapids, Michigan

Alexis R. Jones, Pharm.D., BCOP, CPP
Clinical Pharmacist, Gynecologic Oncology
University of North Carolina Medical Center
Chapel Hill, North Carolina

Elyse A. MacDonald, Pharm.D., M.S., BCPS
Director, Pharmacy Services, Investigational Drug Service
Stanford Health Care
Palo Alto, California

Janelle Mann, Pharm.D., BCOP
Clinical Oncology Pharmacist/Manger, Clinical Pharmacy Services
Alvin J. Siteman Cancer Center/Washington University School of Medicine in St. Louis
St. Louis, Missouri

Anthony J. Perissinotti, Pharm.D., BCOP
Hematology Clinical Pharmacist Specialist
University of Michigan – Michigan Medicine
Ann Arbor, Michigan

Danielle Roman, Pharm.D., BCOP*
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Christine M. Walko, Pharm.D., BCOP, FCCP*
Associate Member, Individualized Cancer Management
H. Lee Moffitt Cancer Center
Tampa, Florida

Jennifer Young, Pharm.D., BCOP
Clinical Pharmacy Specialist – Pediatric Oncology
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio

*Content Matter Experts

Reviewers

Marin Abousaud, Pharm.D., BCOP
Jonathan Angus, Pharm.D., BCOP
Allison Bass, Pharm.D., BCOP
Colleen Bohnenkamp, Pharm.D., BCOP, BCPS
Janet Bramell, Pharm.D., BCPS, BCOP
Theresa Brown, Pharm.D., BCOP, CPP
Ryan Bycroft, Pharm.D., BCOP
Peter Campbell, Pharm.D., BCOP
Ansley Chambers, Pharm.D., BCOP
Soniya Chandrasekhara, Pharm.D.
Kevin Chen, Pharm.D., M.S., BCOP, CPP
Jill Comeau, Pharm.D., BCOP
Wendy Covert, Pharm.D., BCOP
Laura Darland, Pharm.D., BCOP
Sara deHoll, PharmD, BCOP
Kathy Edwards, B.S., Pharm.D., BCPS, BCOP, FHOPA
Bryna Ewachiw, Pharm.D., BCOP
Ashley Glode, Pharm.D., BCOP
Mitchell Hughes, Pharm.D., BCPS, BCOP
Jennifer Hutchinson, Pharm.D., BCOP
Jeff Kaiser, Pharm.D., BCOP, BCPS
Shraddha Kansagra, Pharm.D., BCOP
Jessica LeClair, Pharm.D., M.B.A., BCOP
Matthew Lei, Pharm.D., BCOP
Whitney Lewis, Pharm.D., BCOP
Claire Mach, Pharm.D., BCOP
Jennifer Martin, Pharm.D., BCOP
Colleen McCabe, Pharm.D., BCOP
Donald Moore Pharm.D., BCPS, BCOP, DPLA
Matthew Newman, Pharm.D., MEHP, BCOP
Nancy Nix, Pharm.D., BCPS, BCOP
Carolyn Oxencis, Pharm.D., BCOP
Makenna Smack, Pharm.D., BCOP
Anne Spengler, Pharm.D., BCOP, APh
Kelsey Turcotte, Pharm.D., BCOP
Courtney Watts Alexander, Pharm.D., BCPS, BCOP
Taylor Weis, Pharm.D., BCOP
Lourdes Wong, Pharm.D., BCOP, BCSCP
Lily Yan, Pharm.D., BCOP
Spencer Yingling, Pharm.D., BCOP

Relevant Financial Relationship Disclosure

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

  • Karen Fancher is Consultant, AstraZeneca, LP;  Consultant, Merck & Co.; Consultant, speakers bureau, BTG Specialty Pharmaceuticals
  • Alexis R. Jones is Multidisciplinary Council Member, Eisai; Content developer, KellyCPharmD
  • Anthony J. Perissinotti is Consultant, Amgen; consultant, Pfizer; consultant, Servier
  • Christine M. Walko is Consultant, Foundation Medicine; MTB Consultant, Jackson Genetic Laboratories; MTB Consultant, Intermountain Healthcare

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

Development

These activities were developed by ASHP and ACCP.

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.